12:33:34 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-11-28 15-6 2023
2023-11-17 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-06-14 Ordinarie utdelning EMPLI 0.00 SEK
2023-06-13 Årsstämma 2023
2023-05-12 Kvartalsrapport 2023-Q1
2023-05-02 Extra Bolagsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-11-14 Extra Bolagsstämma 2022
2022-08-18 Kvartalsrapport 2022-Q2
2022-04-26 Kvartalsrapport 2022-Q1
2022-04-07 Ordinarie utdelning EMPLI 0.00 SEK
2022-04-06 Årsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Emplicure utvecklar produkter baserat på kombinationen av redan godkända aktiva substanser och materialvetenskap inom biokeramer, med skräddarsydda frisättningsprofiler som specialitet. Moderbolaget fokuserar på läkemedel, initialt mot kronisk smärta och med egenskaper som motverkar att de kan missbrukas. Via dotterbolag utvecklas konsumentprodukter, med oralt nikotin som första produktlinje. Sortimenten riktar sig till läkemedels- och konsumentnischer.
2023-05-29 12:07:10

TomEQT Private AB ("TomEQT Private") has today announced a mandatory takeover offer in cash for the shares in Emplicure AB (publ) ("Emplicure" or the "Company") at a price of SEK 0.50 per share (the "Offer"). The Offer is made in accordance with the rules regarding mandatory takeover offers since TomEQT Private's shareholding in Emplicure, following the directed issue of shares resolved by the board of directors of Emplicure on 24 May 2023, now amounts to approximately 50.6 percent of the total number of shares and votes in Emplicure.

An offer document regarding the Offer is expected to be published on 29 May 2023. The acceptance period for the Offer is expected to commence on 30 May 2023 and end around 20 June 2023. The expected settlement date is 28 June 2023.

For further information regarding the Offer, please refer to TomEQT Private's announcement of the Offer, which is available on TomEQT Private's website www.tomeprivateab.com.

The board of directors of Emplicure will now evaluate the Offer. The board of directors will, no later than two weeks before the expiration of the acceptance period, publish its opinion and recommendation regarding the Offer and state the reasons for such recommendation. The board member Johan Wieslander will not participate in the board of directors' preparations of or decisions in matters relating to the Offer with reference to that family members of Johan Wieslander and Thomas von Koch (owners of TomEQT Private) have a private friendship relation.

This information is information that Emplicure AB (publ) is required to disclose pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons above, on May 29, 2023 at 12:07 CET.

For additional information, please contact

Håkan Engqvist

CEO
Phone: +46 702 569 500
Email: hakan.engqvist@emplicure.com

Erik Magnusson

CFO
Phone: +46 708 565 245
Email: erik.magnusson@emplicure.com

Certified Adviser

Emplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.

The following documents can be retrieved from beQuoted
PM-Emplicure NE ENG-2023-05-24.pdf

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com